Access the full text.
Sign up today, get DeepDyve free for 14 days.
Maemondo (2010)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med, 362
Y. Koh, Dong-Wan Kim, Tae Kim, Se-Hoon Lee, Y. Jeon, D. Chung, Young-Whan Kim, D. Heo, W. Kim, Y. Bang (2011)
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These TumorsJournal of Thoracic Oncology, 6
L. Tanoue (2011)
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRYearbook of Pulmonary Disease, 2011
Kaplan (1958)
Nonparametric estimation from incomplete observationJ Am Stat Assoc, 53
M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 448
C. Tekle, E. Giovannetti, J. Sigmond, J. Graff, K. Smid, G. Peters (2008)
Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cellsBritish Journal of Cancer, 99
Tsuyoshi Takahashi, M. Sonobe, Masashi Kobayashi, A. Yoshizawa, T. Menju, E. Nakayama, N. Mino, Shotaro Iwakiri, Kiyoshi Sato, R. Miyahara, K. Okubo, T. Manabe, H. Date (2010)
Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion GeneAnnals of Surgical Oncology, 17
S. Rodig, M. Mino‐Kenudson, S. Dacic, B. Yeap, A. Shaw, J. Barletta, Hannah Stubbs, Kenny Law, N. Lindeman, E. Mark, P. Janne, T. Lynch, B. Johnson, A. Iafrate, L. Chirieac (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 15
L. Sequist, S. Gettinger, N. Senzer, R. Martins, P. Jänne, R. Lilenbaum, J. Gray, A. Iafrate, Ryohei Katayama, N. Hafeez, J. Sweeney, J. Walker, C. Fritz, R. Ross, D. Grayzel, J. Engelman, D. Borger, G. Paez, R. Natale (2010)
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 33
T. Ciuleanu, T. Brodowicz, C. Zielinski, J. Kim, M. Krzakowski, E. Laack, Yi-long Wu, I. Bover, StephenD. Begbie, V. Tzekova, B. Čučević, J. Pereira, S. Yang, J. Madhavan, K. Sugarman, P. Peterson, W. John, K. Krejcy, C. Belani (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 374
G. Altavilla, M. Santarpia, C. Arrigo, M. Rizzo, G. Galletti, G. Marabello, A. Gnani, V. Pitini (2010)
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients.Journal of Clinical Oncology, 28
A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung
Zhao Chen, Takaaki Sasaki, X. Tan, J. Carretero, T. Shimamura, Danan Li, Chunxiao Xu, Yuchuan Wang, G. Adelmant, M. Capelletti, Hyun Lee, S. Rodig, Christa Borgman, Seung-Il Park, H. Kim, R. Padera, J. Marto, N. Gray, A. Kung, G. Shapiro, P. Jänne, Kwok-kin Wong (2010)
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.Cancer research, 70 23
H. Ozasa, T. Oguri, T. Uemura, M. Miyazaki, K. Maeno, Shigeki Sato, R. Ueda (2010)
Significance of thymidylate synthase for resistance to pemetrexed in lung cancerCancer Science, 101
A. Shaw, B. Yeap, M. Mino‐Kenudson, S. Digumarthy, D. Costa, R. Heist, B. Solomon, Hannah Stubbs, S. Admane, U. McDermott, J. Settleman, Susumu Kobayashi, E. Mark, S. Rodig, L. Chirieac, E. Kwak, T. Lynch, A. Iafrate (2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
E. Kaplan, P. Meier (1958)
Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 53
T. Nakagawa, Y. Otake, K. Yanagihara, R. Miyahara, S. Ishikawa, M. Fukushima, H. Wada, F. Tanaka (2004)
Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC).Lung cancer, 43 2
Yihua Sun, Yan Ren, Zhaoyuan Fang, Chenguang Li, Rong Fang, Bin Gao, Xiangkun Han, W. Tian, W. Pao, Haiquan Chen, H. Ji (2010)
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 30
Mok (2009)
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med, 361
B. Grønberg, R. Bremnes, O. Fløtten, T. Amundsen, P. Brunsvig, H. Hjelde, S. Kaasa, C. Plessen, Frøydis Stornes, T. Tollåli, F. Wammer, U. Aasebø, S. Sundstrøm (2009)
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 19
Jong-Mu Sun, Keun-Wook Lee, J. Kim, Y. Kim, H. Yoon, Jae-Ho Lee, C. Lee, J. Lee (2008)
Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.Japanese journal of clinical oncology, 39 1
Donghui Li, Jeffrey Morris, Jun Liu, Manal Hassan, R. Day, Melissa Bondy, J. Abbruzzese (2009)
F1000 highlightsAsia‐Pacific Journal of Clinical Oncology, 5
K. Inamura, K. Takeuchi, Yuki Togashi, S. Hatano, H. Ninomiya, N. Motoi, M. Mun, Y. Sakao, S. Okumura, K. Nakagawa, M. Soda, Y. Choi, H. Mano, Y. Ishikawa (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onsetModern Pathology, 22
K. Inamura, K. Takeuchi, Yuki Togashi, K. Nomura, H. Ninomiya, M. Okui, Y. Satoh, S. Okumura, K. Nakagawa, M. Soda, Young Choi, T. Niki, H. Mano, Y. Ishikawa (2008)
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung CancersJournal of Thoracic Oncology, 3
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, Martine Glabbeke, Allan Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumorsBreast Cancer, 12
H. Hashimoto, Y. Ozeki, Mitsuharu Sato, K. Obara, N. Matsutani, Y. Nakagishi, T. Ogata, T. Maehara (2006)
Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lungCancer, 106
L. Ding, G. Getz, D. Wheeler, E. Mardis, M. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D. Muzny, M. Morgan, L. Fulton, R. Fulton, Qunyuan Zhang, M. Wendl, M. Lawrence, D. Larson, Ken Chen, D. Dooling, A. Sabo, A. Hawes, Hua Shen, S. Jhangiani, L. Lewis, O. Hall, Yiming Zhu, T. Mathew, Yanru Ren, Jiqiang Yao, S. Scherer, Kerstin Clerc, G. Metcalf, Brian Ng, A. Milosavljevic, M. Gonzalez-Garay, John Osborne, R. Meyer, Xiaoqi Shi, Yuzhu Tang, D. Koboldt, Ling Lin, R. Abbott, T. Miner, C. Pohl, G. Fewell, C. Haipek, Heather Schmidt, Brian Dunford-Shore, A. Kraja, S. Crosby, Christopher Sawyer, T. Vickery, Sacha Sander, J. Robinson, W. Winckler, J. Baldwin, L. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. Johnson, R. Onofrio, Roman Thomas, G. Tonon, B. Weir, Xiaojun Zhao, L. Ziaugra, M. Zody, T. Giordano, M. Orringer, J. Roth, M. Spitz, I. Wistuba, B. Ozenberger, P. Good, A. Chang, D. Beer, M. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. Travis, W. Pao, M. Province, G. Weinstock, H. Varmus, S. Gabriel, E. Lander, R. Gibbs, M. Meyerson, R. Wilson (2008)
Somatic mutations affect key pathways in lung adenocarcinomaNature, 455
Y. Kim, Tae-You Kim, Dong Lee, Sun Park, Ju-Yeon Park, S. Seo, H. Choi, H. Kang, S. Hahn, C. Kang, S. Sung, Joo Kim (2008)
Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.Lung cancer, 59 1
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.Journal of the National Cancer Institute, 92 3
Myungsook Chang, J. Ahn, Jeeyun Lee, Kyoungha Kim, Yeon-Hee Park, Joungho Han, M. Ahn, Keunchil Park (2010)
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.Lung cancer, 69 3
G. Scagliotti, P. Parikh, J. Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. Marinis, L. Simms, K. Sugarman, D. Gandara (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
N. Hanna, F. Shepherd, F. Fossella, J. Pereira, F. Marinis, J. Pawel, U. Gatzemeier, T. Tsao, M. Pless, T. Muller, H. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, P. Bunn (2004)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon, Robert Maki, Sai-Hong Ou, Bruce Dezube, P. Jänne, Daniel, B. Costa, M. Varella-Garcia, W. Kim, Thomas Lynch, P. Fidias, Hannah Stubbs, J. Engelman, V. Lecia, Sequist, Weiwei Tan, L. Gandhi, M. Mino‐Kenudson, Greg Wei, S. Shreeve, M. Ratain, Jeffrey, Settleman, James Christensen, D. Haber, K. Wilner, R. Salgia, Geoffrey Shapiro, J. Clark, A. Iafrate (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.The New England journal of medicine, 363 18
D. Wong, Elaine Leung, Kimpton So, Issan Tam, A. Sihoe, L. Cheng, Kwok‐Keung Ho, J. Au, L. Chung, Maria Wong (2009)
The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRASCancer, 115
S. Murakami, T. Yokose, H. Saito, Y. Sakuma, S. Matsukuma, C. Hasegawa, T. Kondo, F. Oshita, H. Ito, M. Tsuboi, H. Nakayama, Y. Kameda, K. Noda, Kouzo Yamada (2010)
Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.Lung cancer, 69 3
ORIGINAL ARTICLE Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer Jeong-Ok Lee, MD,* Tae Min Kim, MD,†‡ Se-Hoon Lee, MD,†‡ Dong-Wan Kim, MD,†‡ Soyeon Kim, MS,‡ Yoon-Kyung Jeon, MD,§ Doo Hyun Chung, MD,§ Woo-Ho Kim, MD,§ Young Tae Kim, MD,‡ Seok-Chul Yang, MD,† Young Whan Kim, MD,† Dae Seog Heo, MD,†‡ and Yung-Jue Bang, MD†‡ ung adenocarcinoma is heterogeneous with diverse so- Introduction: This study compared the efficacy of pemetrexed in Lmatic mutations associated with carcinogenesis. Most patients with anaplastic lymphoma kinase (ALK)-positive versus ALK- East Asian patients with lung adenocarcinoma who have negative (epidermal growth factor receptor [EGFR] mutant or wild type never smoked harbor targetable oncogenic mutations, includ- [WT] for both ALK and EGFR) non-small cell lung cancer (NSCLC). ing epidermal growth factor receptor (EGFR) mutations, Methods: Patients with advanced NSCLC who received second-line fusions of echinoderm microtubule-associated protein-like 4 pemetrexed and beyond between March 2007 and April 2010 were (EML4) and anaplastic lymphoma kinase (ALK), and human screened for EGFR mutations and ALK rearrangements at Seoul epidermal growth factor receptor 2. The discovery of these National University Hospital. The clinical and in vitro efficacy of mutations led to
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Sep 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.